Sander A. Vinks, PharmD, PhD, FCP

Director, Division of Clinical Pharmacology

Professor, UC Department of Pediatrics

Adjunct Professor of Pharmacology

Phone 513-636-0159

Fax 513-636-0168

Email sander.vinks@cchmc.org

Dr. Vinks received his MS in pharmacology from the University of Toronto, Canada and a pharmacy degree and PhD in pharmacology from Leiden University, The Netherlands. He was trained as a hospital pharmacist (PharmD) and clinical pharmacologist at The Hague Hospitals Central Pharmacy, The Hague, The Netherlands.

Before joining the Division of Pharmacology Research at Cincinnati Children's Hospital Medical Center, he was director of the Clinical Pharmacology & Toxicology Laboratory at The Hague. Dr. Vinks has spent over 20 years in the field of therapeutic drug monitoring and applied pharmacokinetics, both in the research aspects of population pharmacokinetic studies, as well as in the clinical application of these approaches to clinical patient care.

Dr. Vinks holds an academic appointment with the University of Cincinnati College of Medicine and is the principal investigator for the Pediatric Pharmacology Research Unit (PPRU). He is director of the Laboratory of Applied Pharmacokinetics and Therapeutic Drug Management (LAP/TDM) and clinical pharmacology fellowship program at Cincinnati Children's. His current research interests include pharmacokinetic-pharmacodynamic (PK-PD) modeling and the application of population and simulation methods in TDM and clinical trial design. He has authored over 50 publications in the area of TDM, pharmacokinetics and clinical pharmacology. Dr. Vinks has been actively involved with International Association of Therapeutic Drug Monitoring and Clinical Toxicology from the beginning. He is chair of the TDM cost-effectiveness committee, serves as secretary of the Executive Board of Directors, and is on the editorial board of the journal Therapeutic Drug Monitoring. Dr. Vinks is both board certified in clinical pharmacology and toxicology and is a fellow of the American College of Clinical Pharmacology.

Certification American Board of Clinical Pharmacology, 2001.

PhD Clinical Pharmacology, Leiden University, Leiden The Netherlands, 1996.

PharmD Hospital Pharmacy, The Hague Central Hospital Pharmacy, The Hague, The Netherlands, 1986 .

MS Pharmacology, University of Toronto, Toronto Canada, 1983.

MS Pharmacy, Leiden University, Leiden, The Netherlands, 1982.

Sherwin CM, Fukuda T, Brunner HI, Goebel J, Vinks AA. The evolution of population pharmacokinetic models to describe the enterohepatic recycling of mycophenolic acid in solid organ transplantation and autoimmune disease. Clin Pharmacokinet. 2011 Jan 1;50(1):1-24.

Sagcal-Gironella AC, Fukuda T, Wiers K, Cox S, Nelson S, Dina B, Sherwin CM, Klein-Gitelman MS, Vinks AA, Brunner HI. Pharmacokinetics and pharmacodynamics of mycophenolic Acid and their relation to response to therapy of childhood-onset systemic lupus erythematosus. Semin Arthritis Rheum. 2011 Feb;40(4):307-13.

Mehta PA, Vinks AA, Filipovich A, Bleesing J, Jodele S, Jordan MB, Marsh R, Tarin R, Edwards S, Fearing D, Lawrence J, Davies SM. Alternate-day micafungin antifungal prophylaxis in pediatric patients undergoing hematopoietic stem cell transplantation: a pharmacokinetic study. Biol Blood Marrow Transplant. 2010 Oct;16(10):1458-62.

Fukuda T, Goebel J, Thøgersen H, Maseck D, Cox S, Logan B, Sherbotie J, Seikaly M, Vinks AA. Inosine Monophosphate Dehydrogenase (IMPDH) Activity as a Pharmacodynamic Biomarker of Mycophenolic Acid Effects in Pediatric Kidney Transplant Recipients. J Clin Pharmacol. 2010 Apr 23.

Glauser TA, Cnaan A, Shinnar S, Hirtz DG, Dlugos D, Masur D, Clark PO, Capparelli EV, Adamson PC; Childhood Absence Epilepsy Study Group. Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy. N Engl J Med. 2010 Mar 4;362(9):790-9.

Vargus-Adams JN, McMahon MA, Michaud LJ, Bean J, Vinks AA. Pharmacokinetics of amantadine in children with impaired consciousness due to acquired brain injury: preliminary findings using a sparse-sampling technique. PM R. 2010 Jan;2(1):37-42.

Pestian J, Spencer M, Matykiewicz P, Zhang K, Vinks AA, Glauser T. Personalizing Drug Selection Using Advanced Clinical Decision Support. Biomed Inform Insights. 2009 Jun 23;2:19-29.

Prows CA, Nick TG, Saldaña SN, Pathak S, Liu C, Zhang K, Daniels ZS, Vinks AA, Glauser TA. Drug-metabolizing enzyme genotypes and aggressive behavior treatment response in hospitalized pediatric psychiatric patients. J Child Adolesc Psychopharmacol. 2009 Aug;19(4):385-94.

Prausa SE, Fukuda T, Maseck D, Curtsinger KL, Liu C, Zhang K, Nick TG, Sherbotie JR, Ellis EN, Goebel J, Vinks AA. UGT genotype may contribute to adverse events following medication with mycophenolate mofetil in pediatric kidney transplant recipients. Clin Pharmacol Ther. 2009 May;85(5):495-500.

Rogers CC, Alloway RR, Alexander JW, Cardi M, Trofe J, Vinks AA. Pharmacokinetics of mycophenolic acid, tacrolimus and sirolimus after gastric bypass surgery in end-stage renal disease and transplant patients: a pilot study. Clin Transplant. 2008 May-Jun;22(3):281-91.